A survey of psychiatrists has revealed that Eli Lilly’s Zyprexa (olanzapine) is seen as an improvement over AstraZeneca/Astellas’s Seroquel (quetiapine), the top drug by sales in the bipolar disorder drug market.

According to a Decision Resources report that surveyed professionals in the US, the decreasing of the severity of manic symptoms is the attribute that most influences their prescribing decisions when treating bipolar mania.

The report also found that a therapy that carries a risk of weight gain that is the same as, or better than, Bristol-Myers Squibb/Otsuka Pharmaceutical‘s Abilify (aripiprazole) would earn a higher patient share in Europe than in the US.

According to surveyed European and US psychiatrists, such a therapy would earn a 40% patient share in Europe and a 20% patient share in the US.